Intranasal Flu Vaccine Use in Cystic Fibrosis Patients: Assessing the Risks

Live-Attenuated Flu Vaccine in Pediatric CF: Assessing the Risks
Live-Attenuated Flu Vaccine in Pediatric CF: Assessing the Risks
Children with cystic fibrosis (CF) have an increased risk of morbidity and higher case fatality during the influenza pandemic compared to patients with other chronic respiratory diseases or healthy controls.

OBJECTIVES: Given the improved efficacy of the nasal live-attenuated influenza virus vaccine (LAIV) compared with the injectable vaccine in children, we aimed to determine its safety in individuals with cystic fibrosis (CF). Days 0 to 28 post-LAIV were considered the at-risk period for all outcomes of interest, and days 29 to 56 post-LAIV were considered the non-at-risk period.

READ FULL ARTICLE Curated publisher From Aappublications

  • Latest News Your top articles for Tuesday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More